Hepatoma cell-specific ganciclovir-mediated toxicity of a lentivirally transduced HSV-TkEGFP fusion protein gene placed under the control of rat alpha-fetoprotein gene regulatory sequences

Cancer Gene Therapy

Volumn 10, Issue 9, 2003, Pages 689-695

  Uch, Rathviro ^a,b   Gérolami, René ^a,b   Faivre, Jamila ^b   Hardwigsen, Jean ^c   Mathieu, Sylvie ^b   Mannoni, Patrice ^a   Bagnis, Claude ^a  

^a ETABLISSEMENT FRANÇAIS DU SANG   (France)

^b INSERM   (France)

^c HÔPITAL DE LA CONCEPTION   (France)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; HSV TkEGFP; Lentiviral vector

Indexed keywords

ALPHA FETOPROTEIN; EPIDERMAL GROWTH FACTOR; GANCICLOVIR; GREEN FLUORESCENT PROTEIN; HERPES SIMPLEX VIRUS THYMIDINE KINASE ENHANCED GREEN FLUORESCENT FUSION PROTEIN; HYBRID PROTEIN; LENTIVIRUS VECTOR; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; CELL LINE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SAFETY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL; LIVER CELL CARCINOMA; LIVER PARENCHYMA; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; RAT; REGULATORY SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SUICIDE GENE THERAPY; TRANSGENE;

LENTIVIRUS; SIMPLEXVIRUS;

EID: 0141788260     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700621     Document Type: Article

References (27)

1. Okuda K. Hepatocellular carcinoma. J Hepatol. 2000;32:225-237.
2. Colombo M. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol. 1999;31:25-30.
3. Brechot C, Jaffredo F, Lagorce D, et al. Impact of HBV, HCV and GBV-C/ HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol. 1998;29:173-183.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
5. Deuffic S, Buffat L, Poynard T, et al. Modeling the hepatitis C virus epidemic in France. Hepatology. 1999;29:1596-1601.
6. Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg. 1991;15:270-285.
7. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
8. Bismuth H, Chiche L, Adam R, et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg. 1993;218:145-151.
9. Schlitt HJ, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999;17:324-331.
10. Qian C, Drozdzik M, Caselmann WH, et al. The potential of gene therapy in the treatment of hepatocellular carcinoma. J Hepatol. 2000;32:344-351.
11. Gerolami R, Cardoso J, Lewin M, et al. Evaluation of HSV-tk gene therapy in a rat model of chemically induced hepatocellular carcinoma by intratumoral and intrahepatic artery routes. Cancer Res. 2000;60:993-1001.
12. Brand K, Arnold W, Bartels T, et al. Liver-associated toxicity of the HSV-tk/GCV approach and adenoviral vectors. Cancer Gene Ther. 1997;4:9-16.
13. Bilbao R, Gerolami R, Bralet MP,et al. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocellular carcinoma: the woodchuck animal model. Cancer Gene Therapy. 2000;7:657-662.
14. Brand K, Loser P, Arnold W, et al. Tumor cell-specific transgene expression prevents liver toxicity of the adeno-HSVtk/GCV approach. Gene Therapy. 1998;5:1363-1371.
15. Gerolami R, Uch R, Jordier F, et al. Gene transfer to hepatocellular carcinoma: transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors. Cancer Gene Ther. 2000;7:1286-1292.
16. Park F, Ohashi K, Chiu W, et al. Efficient lentiviral transduction of liver requires cell cycling in vivo. Nat Genet. 2000;24:49-52.
17. Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology. 2002;62(Suppl 1):57-63.
18. Kiwaki K, Kanegae Y, Saito I, et al. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum Gene Ther. 1996;7:821-830.
19. Zufferey R, Donello JE, Trono D, et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol. 1999;73:2886-2892.
20. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263-267.
21. Kaneko S, Hallenbeck P, Kotani T, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 1995;55:5283-5287.
22. Arbuthnot P, Bralet M, LeJossic C, et al. In vitro and in vivo hepatoma cell specific expression of a gene transferred with an adenoviral vector. Hum Gene Ther. 1996;7:1503-1514.
23. Arbuthnot P, Bralet M-P, Thomassin H, et al. Hepatoma cell-specific expression of a retrovirally transferred gene is achieved by alpha-foetoprotein but not insulin-like growth factor II regulatory sequences. Hepatology. 1995;22:1788-1796.
24. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.
25. Kanai F, Shiratori Y, Yoshida Y, et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology. 1996;23:1359-1368.
26. Gouillat C, Manganas D, Zoulim F, et al. Woodchuck hepatitis virus-induced carcinoma as a relevant natural model for therapy of human hepatoma. J Hepatol. 1997;26:1324-1330.
27. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med. 2000;2:148-164.